Floatz logo

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)

Advanced or Metastatic Solid Malignancies

National Cancer Institute (NCI)antibody_drug_conjugatePhase 2/3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

275 Active assets in the Advanced or Metastatic Solid Malignancies cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
FILGRASTIM
Mayo Clinic
Phase 3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:

urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urinary bladder neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
ureter neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →